Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib + abiraterone in bone-metastatic CRPC
NCT01995058Phase 2Terminated
- Sponsor
- Exelixis, Inc.
- Start
- Feb 2014
- Primary completion
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of cabozantinib in castration-resistant prostate cancer (CRPC) (4 arms), sponsored by Exelixis, Inc. Primary endpoint: Radiographic Progression-Free Survival at 18 months. Started Feb 2014; status: terminated.
02
Drugs
cabozantinib
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT01995058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01995058.